Phase I Study to Evaluate Treatment of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Chimeric Antigen Receptor (CAR) T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Official Summary

Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric antigen receptor (CAR) T cells to effect the immuno-microenvironment around tumors.

Study Design

• Study Type: INTERVENTIONAL
• Allocation: NA
• Model: SINGLE_GROUP
• Masking: NONE
• Enrollment: 10 participants

Interventions

• BIOLOGICAL: anti-mesothelin CAR-T cells — Cells will be infused on day 0.

Primary Outcomes

• study of related adverse events (24 weeks)

Secondary Outcomes

• clinical responses to anti-mesothelin cell infusions (24 weeks)

Trial Locations

• Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, China

More Solid Tumor, Adult Trials

View all Solid Tumor, Adult clinical trials